DZ Bank’s Spyre Therapeutics SYRE Stock Holding History

DZ Bank’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,618	Closed	-$649K	–	1073
2018 Q1	$649K	Buy	+2,618	New	+$473K	﹤0.01%	750

Other funds holding SYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

DZ Bank's SYRE Position: Q2 2018 in Review

DZ Bank sold out of Spyre Therapeutics (SYRE) in Q2 2018, closing a stake of 2,618 shares — an estimated $649K sold.

DZ Bank first reported a position in SYRE in Q1 2018 and held it in 1 quarter. The position peaked at $649K in Q1 2018. 64 funds tracked by Wall St. Rank hold SYRE as of Q2 2018.

DZ Bank reported no remaining Spyre Therapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 2,618 Spyre Therapeutics shares in Q2 2018, an estimated $649K.
DZ Bank first reported a position in Spyre Therapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Spyre Therapeutics position peaked at $649K in Q1 2018.
64 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.